The UDP-glucuronosyltransferase UGT1A gene is a major biotransformation gene involved in the metabolism of a vast array of molecules. Recently, we uncovered a new series of alternative spliced isoforms referred to as isoforms 2 or UGT1As_i2 that use an alternative exon 5 (5b). The function of such mRNAs and the corresponding 45 kDa proteins still remains unclear. Although devoid of glucuronosyltransferase activity, UGT1As_i2 are widely co-expressed with the enzymatically active and classical UGT1A isoforms (UGT1As_i1). In this study, we observed abundant signal in human colon tissue samples, predominantly along intestinal crypts. In human cells, UGT1A_i2 proteins are expressed in similar subcellular compartments as UGT1As_i1. Cellular properties of i2-spliced forms were then studied using synthetic small-interfering RNA (siRNA) in two human colon cancer cell lines that show a significant amount of exon 5a-and exon 5b-containing mRNAs and that display enzymatic activities for UGT1As substrates. We observed that siRNA-mediated knockdown of endogenous i2 upregulates cellular glucuronidation activities by 120-170% (Po0.01) for all substrates tested. Functional data support a dominant-negative function for endogenous exon 5b-spliced forms of UGT1A, hence potentially affecting in vivo glucuronidation capacity. This new regulatory strategy may ensure an additional mean to modulate cellular response to endo/xeno stimulus.
Introduction
The glucuronidation pathway is a major cellular process of conjugative metabolism for a large number of xenobiotics and endobiotics. This phase II metabolic pathway is particularly significant in the liver but also in the kidney and the gastrointestinal tract. The microsomal UDP-glucuronosyltransferase enzymes (UGTs) responsible for glucuronidation obviously contribute to the pharmacokinetics and biological effects of drugs, as well as other environmental or endogenous compounds. 1 A significant number of human UGTs are encoded by a single gene locus UGT1A, on chromosome 2q37 that has a remarkable genomic structure leading to protein diversity. This gene is submitted to alternative promoter usage resulting in nine functional enzymes, plus four pseudoexons, with different N-termini and identical C-termini. 2, 3 The UGT1As have unique exons 1 encoding the substrate recognition domain regulated by its own promoter but share the rest of their coding sequences involved in co-substrate binding. Further genetic variability in the specific UGT1A coding and non-coding sequences has been exemplified by the presence of several polymorphisms that contribute to the interindividual variability of this pathway (for a complete list of UGT1A polymorphisms see http://www.ugtalleles. ulaval.ca). 4, 5 Until recently, no evidence of alternative splicing in the region of common exons (exons 2-5) has been shown for the UGT1A gene complex (GenBank AF297093). However, following the isolation of an UGT1A cDNA lacking C-term region from human kidney, the entire locus was screened for additional exons and a new alternative exon was uncovered between the coding exons 4 and 5, named exon 5b. The latter is alternatively used to exon 5a (the classical exon 5) leading to new UGT1A mRNA variants with alternative 3 0 -end (called isoforms 2 or i2) that have a tissue distribution similar to UGT1A functional transferase enzymes (called isoforms 1 or i1). The presence of exon 5b in the mRNA sequence induces the replacement by a 10-amino acid sequence of the residues 435-533 encoded by exon 5a, leading to products with a distinctive C-term feature but retaining the co-substrate-binding domain. 6, 7 Further works revealed by the heterologous expression of novel UGT1A_i2 proteins indicate that these spliced forms have undetectable glucuronic acid transferase activity and are therefore enzymatically inactive. Expression studies with microsomes prepared from human tissues using currently available anti-UGT antibodies have highlighted that hepatic but particularly extrahepatic tissues may be a predilection site for those new alternative splicing events.
Based on these previous observations, the investigation of the physiological role of i2 products was at the center of this study. Here, we first addressed whether the exon 5b-containing mRNAs are translated in vivo by performing immunohistochemical experiments in human tissues. The specific expression of UGT1A_i2 proteins was evaluated using a recently developed polyclonal antibody against the exon 5b-derived peptide. The same approach was used to assess if UGT1A_i2 proteins are expressed in similar subcellular compartments as UGT1A_i1 enzymes. Our approach was then to test whether the endogenous cellular levels of UGT1A_i2 species affect i1-mediated transferase activity in cells naturally expressing both UGT1A-spliced forms. This premise arises from the fact that we previously showed that the presence of i2 induces a significant repression of glucuronidation activity upon heterologous co-expression of i1 and i2 proteins in HEK293 cells. Synthetic small-interfering RNA (siRNA), targeted to the alternative exon 5b was used to specifically repress endogenous UGT1As_i2 in colon cells, and to test intrinsic glucuronidation capacity of cells post-treatment. Results of these investigations clearly show that endogenous i2-spliced forms are present in human tissues, co-localize with i1 proteins and that changes in their expression level significantly regulate the metabolic capacity of cells. We conclude to a dominant-negative role for endogenous i2-spliced forms of UGT1A. 
Materials and methods

Materials
Characterization of a new polyclonal anti-UGT1A isoforms 2 antibody
The classical UGT1As were named isoforms 1 (UGT1As_i1) and the spliced forms UGT1A proteins (containing the new exon 5b sequences) are referred to as isoforms 2 (UGT1A-s_i2) in accordance with the Human Gene Nomenclature Guidelines and following agreement with the UGT nomenclature committee. 7 Anti-exon 5b antibody was raised against amino acids encoded by exon 5b, a 10 amino acids length region, common and specific to all UGT1A_i2 proteins. Rabbits from Charles River Laboratories Inc., (Québec, Canada) were injected with a total of 100 mg of purified protein in phosphate-buffered saline, in the presence of complete Freund's adjuvant. Two booster injections were administered at 4-week intervals with the same quantity of protein in the presence of incomplete Freund's adjuvant. The production of antibodies in the rabbit's serum was studied 12 days after the second injection, and the rabbits were killed 10 days after the third injection. The specificity of the novel anti-exon 5b no. 4863 antibody was studied by western blotting using 10 mg of UGT1A_i1 microsomal proteins and 1-2 mg of UGT1A_i2 microsomal preparations from human UGT1A1, 1A8, 1A9 and 1A3 overexpressed individually in HEK293 cells. The SDS-PAGE was transferred onto nitrocellulose membranes and incubated with anti-exon 5b no. 4863 antibody (dilution 1:4000). An anti-rabbit IgG horse antibody conjugated with peroxidase (Amersham Biosciences) was used as the second antibody, and the resulting immunocomplexes were visualized using a chemiluminescence kit (Renaissance, Quebec, Quebec, Canada) and exposed on HyperfilmTM (Eastman Kodak Co). Those experiments showed that the immune serum no. 4863 is immunoreactive exclusively for UGT1A isoform 2 proteins. Microsomal preparations of UGT1A_i1 (1-40 mg) and UGT1A_i2 (40-80 mg) were used to confirm overexpression of each UGT in cell lines and probed with either the anti-exon5b antibody or a specific polyclonal anti-human UGT1A common carboxyl-terminus region (amino acids 312-531) RC-71 that recognizes the carboxylterminus region common to all UGT1A isoforms. 8 Immunohistochemistry of UGT1A proteins in colon samples All subjects from whom tissues were studied provided written consent for experimental purposes, and the Institutional Review Boards approved the use of these samples. Immunohistochemistry experiments were performed on three normal and malignant colon samples, as described previously. 9 Tissues were incubated with non-immune rabbit serum followed by incubation with the secondary antibody as negative controls. Immunostaining of UGT1A proteins were performed using the anti-human UGT1A RC-71 (dilution 1:250).
8 UGT1A_i2 proteins were labeled using anti-exon 5b antibody no. 4863 described here (dilution 1:250) and finally, the anti-UGT1A1 antibody, raised against the NH 2 terminus from amino acid 63-144 of the UGT1A1 protein (dilution 1:500), was also tested. mRNA expression analyses Total RNA was isolated from cells according to the TriReagent acid phenol protocol as specified by the supplier (Molecular Research Center Inc., Cincinnati, OH, USA). Total RNA was resuspended in RNAsecure Resuspension Solution and heated to 60 1C for 10 min (Ambion, Austin, TX, USA). RNA samples were subjected to Turbo DNA-free treatment (Ambion, Austin, TX, USA). Reverse transcription reaction was performed using 1-2 mg of total RNA with 100 units of Superscript II (Invitrogen).
Specific strategies were designed for UGT1A-spliced forms 1 and 2 and UGT2B7 amplifications. Expression levels were normalized for r18S content. For each reaction, which was done in triplicate in a single experiment, 30 ng of cDNA was amplified in a 20 ml reaction containing 200 nM of each set of primers and 1 Â SybrGreen PCR Master Mix (Applied Biosystems, Warrington, UK). The absolute quantification of samples was determined using the ABI Prism 7000 SDS v1.1 technology (Applied Biosystems, Warrington, UK). Conditions for real-time PCR were 95 1C for 10 min, 95 1C for 15 s and 60 1C (UGT1A i1 and i2, 18S) or 62 1C (UGT2B7) for 60 s for 40 cycles. The C t values of UGT1A-spliced forms 1 and 2 and UGT2B7 were normalized with the internal control 18S (DC t ¼ C t gene of interest-C t 18S). DDC t were obtained by normalizing exon 5b siRNA-transfected with non-target siRNA-transfected cells.
The presence of individual UGT-spliced isoforms 1 and 2 (Supplementary Figure S1) was assessed using sense primers specific for each exon 1 with antisense primers specific for exon 5a and 5b, as described previously. 6 All amplification reactions were repeated at least twice in duplicate for both cell lines using independent RT reactions, and positively controlled in tissue expressing UGT of interest. GAPDH was amplified in each RT reaction as a positive RT-PCR control. The identity of all amplicons was confirmed by sequencing. One-fifth of each RT-PCR was loaded on the gel.
Immunofluorescence Native HT-115 and LOVO cells were used (150 000 cells) for endogenous staining of i2 proteins using the newly developed rabbit antibody anti-exon 5b (no. 4863 at 1:100 dilution) described above. Goat anti-rabbit secondary antibody 1:500 Alexa Fluor 488 was used. Cells were incubated with non-immune rabbit serum followed by incubation with the secondary antibody as negative controls. The expression of the ER-resident protein calnexin was also assessed using a rabbit anti-calnexin primary antibody (Stressgen Biotechnologies, Victoria, Canada) diluted 1:200. Visualization and image acquisition was achieved using a confocal microscope Olympus FV300.
Western blot experiments HT-115 and LOVO cell homogenates were prepared in phosphate-buffered saline solution with dithiothreitol (0.5 mM). For western blot experiments, 40 mg of total proteins were loaded on an SDS-PAGE gel (10%). Proteins were visualized with the rabbit anti-exon 5b (no. 4863 at 1:4000 dilution) and the anti-calnexin antibodies (1:5000 dilution) as internal control (Stressgen, Victoria, British Columbia, Canada). Same experiments were repeated and probed with polyclonal anti-human antibody RC-71 to control for UGT1A_i1 expression levels.
UGT enzymatic assays
All enzymatic assays were performed using 50 mg cell homogenates and incubated for 60 min (bilirubin, SN-38, mycophenolic acid) or 3 h (estradiol) at 37 1C with 200 mM of substrate. Bilirubin and estradiol assays were terminated with 100 ml ice-cold methanol (0.02% butylated hydroxytoluene) and 100 ml ice-cold methanol, respectively, whereas SN-38 and MPA were stopped with 100 and 200 ml ice-cold methanol (1% HCl 2 N). All bilirubin assays were performed under minimal light conditions. Assays were then centrifuged at 14 000 g for 10 min before analysis.
Glucuronide formation was measured by HPLC-MS/MS as
Physiological function of UGT1A_i2 spliced forms J Bellemare et al described 6, 7, 11, 12 and was reported as glucuronidation rates (area or pmol min -1 mg -1 protein).
Statistical analysis
Enzymatic assays were performed in triplicate in at least three independent experiments and were expressed as mean±s.d. Differences in glucuronidation rates were evaluated for statistical significance by the paired Student's t-test. All tests were two-sided.
Results
Endogenous expression of UGT1A-spliced isoforms in human colon tissues In a previous study, the presence of endogenous i2 proteins in microsomal preparations of human tissues was shown by western blot analyses. 6 These experiments were conducted using two anti-UGT1A antibodies that recognize classical 55 kDa UGT1As_i1 and proteins of 45 kDA corresponding to UGT1A_i2 isoforms. The highest UGT1A_i2 proteins expression was observed in gastrointestinal tissues. Here, by using a specific polyclonal antibody raised against the exon 5b-encoded peptide that specifically recognized the i2-spliced forms (Figure 1 ), we initially sought to evaluate their presence and also their cellular localization in human colon tissues, along with active UGT1A transferases corresponding to the classical exon 5a-containing spliced isoforms.
These experiments clearly show the presence of UGT1A_i2 proteins in situ in normal and malignant human colon tissues ( Figure 2 ). Immunostaining using either specific antibodies to all human UGT1As (Ab RC-71), UGT1As_i2 (Ab no. 4863) or UGT1A1 i1 and i2 (Ab no. 518) showed the presence of immunoreactive structures. Luminal cells lining Physiological function of UGT1A_i2 spliced forms J Bellemare et al the intestine were strongly reactive, decreasing in intensity along the crypt. This expression profile shows similar immunoreactive structures for all antibodies, that is, stromal, endothelial and mononucleate cells, with no obvious differences between normal (n ¼ 3) and tumor (n ¼ 3) tissues. Moreover, similarities between immunostaining profiles of all UGT1As and i2-specific staining profile suggest that i2-spliced forms would follow the same protein synthesis and exportation pathways as other endoplasmic reticular UGT1As.
Characterization of cellular models for functional studies Given the demonstration of endogenously expressed spliced forms i2 in colon tissues and their co-localization with Figure 3 Relative mRNA expression levels for UGT1A isoforms 1 and 2 and catalytic activity of human cell lines on bilirubin and mycophenolic acid. (a) Experimental design to specifically amplify UGT1A isoform 1 (i1) and isoform 2 (i2) mRNAs is shown. Common sense primers with two specific antisense primers for UGT1A_i1 (5a), and UGT1A_i2 (5b) mRNAs were used for real-time PCR strategies. Sense and antisense oligonucleotides for i1 and i2 amplicons are indicated by arrows. (b) UGT1A_i1 and UGT1A_i2 mRNA levels were quantified using real-time PCR and normalized to 18S mRNA levels in two liver and four colon cell lines. (c) Glucuronidation assays were performed using 50 mg cell homogenates and incubated for 60 min at 37 1C with 200 mM of each substrate. Glucuronide formation was quantified by liquid chromatography/mass spectrometric analysis. Data represent means ± s.d.
Physiological function of UGT1A_i2 spliced forms J Bellemare et al enzymatically active UGT1As_i1, further studies on the role of these novel proteins were pursued in cellular models of this tissue. To select convenient cellular models, we initially analyzed two commonly used human liver models and four human colon carcinoma cell lines, namely HUH-7, HepG2 and HT-29, HCT-116, HT-115 and LOVO cell lines to characterize endogenous expression of i1 and i2 isoforms (Figure 3 ). Real-time PCR quantification of UGT1A mRNA species showed higher levels of exon 5b-containing mRNAs (i2) in colon-derived cells compared with liver cells, with the highest levels in HT-115 and LOVO cell lines (Figure 3b ). Enzymatic activities, derived from microsomal preparations of these cell lines, are consistent with mRNA expression profiles. HT-115 and LOVO cell lines displayed high catalytic activity toward bilirubin (a specific substrate of UGT1A1) 13 and MPA (a substrate of UGT1A8 and UGT1A9) 11 ( Figure 3c ). Glucuronidating activity for estradiol and irinotecan's active metabolite SN-38, both conjugated by multiple UGT1A isoforms 1, 12, 14, 15 was also significant in these two cell lines (data not shown).
Accordingly, HT-115 and LOVO cell lines were selected for further functional characterization.
Immunofluorescence analyses confirmed protein expression of i2 species in these cells using antibody anti-exon 5b (Ab no. 4863) (Figure 4 ). Similar to classical isoforms i1, [16] [17] [18] [19] i2 proteins are expressed to the endoplasmic reticulum and perinuclear structure. Subsequent localization analyses of calnexin, an ER-resident protein confirmed the localization of i2 to the ER, showing a similar labeling profile.
Depletion of UGT1A isoform 2 mRNAs by transfection with specific siRNA results in a substantial increase of glucuronidation activity in human cells To assess the function of endogenous i2 proteins, specific interfering RNA molecules against UGT1As_i2 were designed in exon 5b to indistinctively target all i2-spliced forms. Upon treatment, we observed a significant decrease of 52 and 59% of exon 5b-containing mRNAs as compared with 18S rRNA in HT-115 and LOVO cells, respectively. In contrast, exon 5a-containing mRNAs corresponding to UGT1A_i1 isoforms, as well as a non-related gene, such as UGT2B7, remained unchanged compared with non-target siRNA (control), thus supporting an effective and specific mRNA knockdown of UGT1As_i2 (Figures 5a and b) .
Then, to ascertain whether decrease in mRNA levels is followed by a corresponding diminution of proteins, total cellular proteins from treated and untreated cells were visualized by western blot analyses with the antibody anti-UGT1A_i2 isoforms. As expected, densitometric analysis of western blots showed a reduction of 80 and 82% of UGT1A_i2 proteins in both cell lines, respectively (Figure 5c ). On the other hand, UGT1As_i1 protein levels remained unaffected. These observations thus showed that the exon 5b-targeted siRNA drastically affects the synthesis of spliced isoform 2 proteins in both cellular models.
Cell homogenates from exon 5b siRNA-treated cells were subsequently assessed for glucuronidation activity of various UGT1A substrates, and compared with cells transfected with non-target siRNA. The UGT1A1-mediated glucuronidation of bilirubin was enhanced by 166 and 129% (Po0.01) in HT-115 and LOVO cells, respectively (Figures 6  and 7) . Similarly, SN-38 glucuronidation was enhanced in both cell lines, as for estradiol-3G formation, both known to be catalyzed by multiple UGT1As. Then, UGT1A8 and UGT1A9-mediated glucuronidation of MPA was also increased, consistent with an inhibition of several i2 isoforms in the presence of the siRNA targeted to exon 5b. Basal enzyme activities were shown to be consistent with expression profiles for specific UGT1A isoforms in these cell lines (for example, high UGT1A1 expression was associated with higher bilirubin glucuronidating activity) (Supplementary Figure S1 ).
This striking effect upon glucuronidating function of cells observed for multiple substrates clearly indicates an endogenous repressive role for spliced isoforms 2 on glucuronidation activity. 
Discussion
It is now well established that alternative exon usage is a common phenomenon in eukaryotic genes, with recent works estimating that over 90% of human genes would conduct to alternatively spliced mRNA isoforms. 20 Accordingly, it is not surprising to associate such mRNA isoforms to a particular gene such as UGT1A. However, to determine whether spliced variants have a biological relevance is much more challenging. Our current work in two colon cancer cell lines expressing both endogenous UGT1A_i1 and UGT1A_i2-spliced forms, as observed for human normal and tumoral colon tissues, supports a functional role for spliced forms 2 of the UGT1A gene in which they would act as negative-dominant regulators of glucuronidation activity.
Previously, we uncovered new mRNA-spliced forms having an unusual 3 0 -end compared with known UGT1A enzymes. In fact, we showed that this is the result of alternative splicing events occurring in the common region of the gene, involving an alternative last exon (exon 5b). Initial in vitro experiments, using a heterologous expression system, first indicated that such spliced forms may be transcribed and then translated to shorter UGT1A polypeptides of 45 kDa named isoforms 2 or i2. Using the same model, we also showed that these new polypeptides lack glucuronic acid transferase activity and that they negatively modulate glucuronidation activity mediated by microsomes expressing active classical UGT1As, named isoforms 1. Indeed, all isoforms 2 were firstly tested for transferase activity with microsomes and UDP-GlcA as co-substrate in standard conditions of glucuronidation assays. For each UGT1A_i2, no glucuronide formation could be detected. 6 Besides, when we co-expressed i1 and i2 species in HK293 cells, rates of glucuronidation were significantly decreased compared with cells expressing exclusively UGT1As_i1. These previous results indicated that isoforms 2 would be enzymatically inactive but that they function as modulators of glucuronidation activity mediated by UGT1A_i1 species. However, this was established in the context of overexpression of both UGT1A-spliced forms in a cellular model lacking endogenous glucuronidation activity (HEK293). 6, 7 In this study, by studying human tissues and human tumorderived cell lines, we intended to undoubtedly show the endogenous protein translation of spliced UGT1A_i2 forms in tissues, and assess their natural ability to modulate UGT1A-mediated glucuronidating activity.
Highly expressed in normal and malignant colon tissues, novel UGT1As_i2 appear to particularly be present in epithelial cells of the intestinal mucosa. In fact, this expression profile is very similar to the one previously described for other UGTs. 21 The co-localization further supports that exon 5b-containing mRNAs are processed in translational pathways similar to other UGT1As. Moreover, according to the sequence similarity between both i1 and i2 proteins, they are likely to localize in the same subcellular Figure 5 Expression of UGT1As in colon cancer cells transfected with non-target or exon 5b siRNA probes. HT-115 and LOVO cells were transfected with 50 nM of non-target (control) or exon 5b siRNA and cultured for 48 h (mRNA) and 96 h (proteins). UGT1A isoforms 1 (i1), UGT1A isoforms 2 (i2) and UGT2B7 (as negative control) mRNA levels were quantified using real-time PCR and normalized to 18S mRNA levels in HT-115 (a) and LOVO (b) cells. Data expressed as mean ± s.d. of three independent experiments performed in triplicate. (c) Cell homogenates were prepared 96 h post-transfection and inhibition of UGT1A_i2 protein synthesis in HT-115 and LOVO cells was confirmed by western blot analysis using a specific anti-UGT1A_i2 polyclonal antibody (Po0.05), whereas UGT1A_i1 protein levels or calnexin, used as positive control for protein loading, remained statistically unchanged.
Physiological function of UGT1A_i2 spliced forms J Bellemare et al structures. Whether they might interact between each other or with other metabolic enzymes in vivo remains to be elucidated, but this is plausible based on previous co-immunoprecipitation experiments with overexpressed proteins. [22] [23] [24] The experimental evidence that UGT1A_i2 proteins are strongly expressed in colon tissue samples was supporting the choice of colon-derived cell lines as models to investigate the potential biological role of these new spliced variants. Among these, HT-115 and LOVO colon cancer cell lines have been chosen for (i) their capacity to express high levels of exon-5b-containing mRNA isoforms and (ii) the production of a broad spectrum of active UGT1A enzymes, supported by elevated basal catalytic UGT activities against typical substrates of the UGT1A family. To examine the functional role of spliced i2 proteins upon basal glucuronidation activity of human cells, we selected to silence the production of i2 proteins by targeting the i2 mRNAs with a specific siRNA. According to our previous data with a heterologous overexpression system, siRNAinduced UTG1As_i2 inhibition would conduct to an enhanced glucuronidation activity of cells. Indeed, i2 proteins expression was successfully and specifically abolished, and this led to a significant enhancement of glucuronidation activity for all UGT1A substrates tested (up to 170% increased UGT activity; Po0.01), namely for bilirubin, SN-38, estradiol and mycophenolic acid. The repressive effect of i2 was observed in cells that showed varied expression levels of i1 and i2 mRNAs; HT-115 showing about 80% of i2 relatively to i1, whereas LOVO cells expressed 50% of i2 compared with i1 expression level. Data from siRNA experiments also support the appropriateness of using a heterologous expression system to study the regulatory properties of i2 proteins on UGT1A isoforms 1-mediated glucuronidation.
The dominant-negative activity associated with spliced variants has been extensively reported for various cellular processes. For instance, the enzymatic activity of laforin, which is a pivotal protein phosphatase in neuronal function, is prevented by the interaction with the non-functional and shorter laf317-spliced variant. 25 The Peroxisome proliferator-activated receptor-g gene also produces an alternative spliced variant called gORF4 that has lost transactivation potential, and interferes with the wild-type. 26 Other examples of spliced variant-induced dominant-negative regulation includes the glucocorticoid receptors, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors and the transcription factor CCAAT/enhancer-binding protein, Figure 6 Glucuronidation rates of (a) bilirubin, (b) SN-38, (c) estradiol and (d) mycophenolic acid in exon 5b siRNA-transfected HT-115 cells. HT-115 cells were transfected with 50 nM of non-target (control) and exon 5b siRNA probes, and cell homogenates were prepared 96 h post-transfection. Glucuronidation assays were performed using 50 mg cell homogenates and incubated for 60 min (bilirubin, SN-38, mycophenolic acid) or 3 h (estradiol) at 37 1C with 200 mM of substrate. Glucuronide formation was quantified by liquid chromatography/mass spectrometric analysis. Data represent means ± s.d. of three independent experiments performed in triplicate. *Po0.01; **Po0.0005 and ***Po0.00001.
Physiological function of UGT1A_i2 spliced forms J Bellemare et al to name only a few. [27] [28] [29] Interestingly, this type of regulation of various cellular processes was all dependent on proteinprotein interactions. Previous co-immunoprecipitation assays, 7 together with the co-localization of isoforms 1 and 2 proteins reflected by immunohistochemistry and subcellular immunofluorescence analyses, also support an inhibition by heteromeric interaction. Furthermore, there is compelling evidence indicating that UGTs are oligomeric enzymes, and previous studies report that enzymatic activity of UGT could be affected by interaction between monomers through homo-and/or hetero-dimerization. [22] [23] [24] In addition, considering that mRNA and protein levels of UGT1A_i1 were unaffected upon siRNA-mediated depletion of endogenous i2 proteins in HT-115 and LOVO cell lines, it is unlikely that UGT1As_i2 associated inhibition be through regulation of mRNA or protein abundance. On the other hand, the mechanism of inhibition by i2 proteins might occur via sequestration of substrate and/or co-substrate molecules, as both isoforms 1 and 2 include the substrate and co-substrate-binding sites. Additional investigations are required to elucidate mechanism(s) involved in this post-transcriptional regulation of the UGT1A glucuronidation activity.
Alternative splicing is a genetic process for controlling gene expression and cellular function through variation in levels of active proteins much more important than thought at the time of its discovery. 20 Our observations are undoubtedly a striking example of the existence of a regulatory mechanism for this metabolic process other than genomic sequence variations and transcriptional mechanisms. However, the mechanism(s) precisely involved in the negative regulation of cellular glucuronidating activity by novel spliced forms have to be further explored. We suspect that active and inactive spliced protein products may physically interact but whether it is dependent on similarity between N-terminal domains of UGT1A proteins (for example UGT1A1_i1 vs UGT1A1_i2) remains to be elucidated. Indeed, a clear limitation of our investigation is the fact that although we confirmed that UGT1A_i2 protein species interfere with glucuronidation activity mediated by UGT1A_i1 enzymes, it is unclear if this inhibition is dependent on sequence similarity (that is, UGT1A1_i2 specifically inhibits UGT1A1_i1) or whether one shorter UGT1A_i2 isoform may influence several UGT1A_i1 enzymes. In fact, it was structurally unachievable to knockdown a specific UGT1A_i2 with synthetic small-interfering RNA covering sequences Figure 7 Glucuronidation rates of (a) bilirubin, (b) SN-38, (c) estradiol and (d) mycophenolic acid in exon 5b siRNA-transfected LOVO cells. LOVO cells were transfected with siRNA non-target (control) and exon 5b, and cell homogenates were prepared 96 h post-transfection. Glucuronidation assays were performed using 50 mg cell homogenates and incubated for 60 min (bilirubin, SN-38, mycophenolic acid) or 3 h (estradiol) at 37 1C with 200 mM of substrate. Glucuronide adducts were measured by liquid chromatography/mass spectrometric analysis. Quantification is expressed as mean ± s.d. of three independent experiments performed in triplicate. *Po0.01; **Po0.0005 and ***Po0.00001.
other than the exon 5b (the only sequence specific to i2), without affecting the corresponding UGT1A_i1 isoform. We suspect that active and inactive spliced protein products may physically interact, but whether such interactions are restricted between corresponding UGT1A isoforms 1 and 2, e.g. UGT1A1_i1 vs UGT1A1_i2, will deserve further investigations. On the other hand, the observation that UGT1As_i2 partially depleted cells have a substantial enhanced glucuronidating activity against all analyzed UGT1A-associated substrates, suggests a significant and complex interplay between both i1 and i2 species. Still, the mechanism(s) precisely involved in the negative regulation of cellular glucuronidating activity by novel spliced forms have to be further explored. Understanding of this post-transcriptional regulation will be of a great interest as an alternative route to modulate glucuronidation activity for future therapeutic applications.
In summary, we initially confirmed that new UGT1A alternatively spliced mRNA species, called UGT1As_i2, conduct to shorter UGT1A polypeptides in vivo, thus ruling out the possibility of artefactual observations because of the use of heterologous overexpression models or due to microsomal preparations. Immunohistochemical analyses also indicate that spliced protein products co-localize with classical UGT1As_i1 enzymes, being expressed to the endoplasmic reticulum and perinuclear structure as shown by immunofluorescence data. Functional analyses by siRNA-induced UGT1As_i2 depletion in colon cells further argue for a modulation of UGT1A activity by i2 forms likely occurring by a mechanism independent of both mRNA and protein degradation, such as protein-protein interaction as reported for other dominant-negative models. Finally, these data raise the possibility that balance of endogenous i1 and i2 proteins would be determinant for glucuronidation activity. This new uncovered mechanism of regulation of UGT1A enzymatic activity, which might be extended to other UGTs, deserves to be more deeply investigated.
Conflict of interest
The authors declare no conflict of interest. 
Abbreviations
